Safe Medicine Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Feb 26, 2020)
Safe Medicine Act
This bill authorizes the Food and Drug Administration to temporarily ban the sale of a drug if (1) the drug (or an active ingredient of the drug) is manufactured in a country that, because of systemic problems of supervision, may be producing contaminated drugs; and (2) the drug's labeling does not have certain warnings about potential contamination.
The bill also requires the Department of Health and Human Services to report to Congress on vulnerabilities in the U.S. medicine supply chain, including vulnerabilities related to reliance on production from other countries.
What just happenedFeb 26, 2020
Referred to the House Committee on Energy and Commerce.
Who’s behind it
- Introduced in HouseFeb 26, 2020
- Feb 26, 2020IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Feb 26, 2020IntroReferralIntro-H
Introduced in House
- Feb 26, 2020IntroReferral1000
Introduced in House